SEC Form 4 · accession 0000899243-17-022152
APPLIED GENETIC TECHNOLOGIES CORP · AGTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Feinsod
Officer — Interim Chief Medical Officer
Period of report
Sep 14, 2017
Accepted (ET)
Sep 15, 2017 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001273636
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 14, 2017 | A | 10,000 | $0.00 | A | 27,648 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The common stock shall vest on December 11, 2017, provided that Mr. Feinsod has remained employed as Interim Chief Medical Officer through such date; however, if Applied Genetic Technologies Corporation elects to terminate Mr. Feinsod's employment as Interim Chief Medical Officer on or before December 11, 2017, the shares shall vest on the date of termination.